Published in final edited form as:

Bioorg Med Chem Lett. 2012 November 1; 22(21): 6642–6646. doi:10.1016/j.bmcl.2012.08.108.

Anti-HIV-1 Activity of Resveratrol Derivatives and Synergistic Inhibition of HIV-1 by the Combination of Resveratrol and Decitabine

Christine L. Clouser^{a,b,*}, Jay Chauhan^c, Matthew A. Bess^{a,b}, Jessica van Oploo^{a,b,c}, Ding Zhou^c, Sarah Dimick-Gray^c, Louis M. Mansky^{a,b,c,d}, and Steven E. Patterson^{a,c,e,*}

^aInstitute for Molecular Virology

^bDepartment of Diagnostic and Biological Sciences, School of Dentistry

^cCenter for Drug Design, Academic Health Center

^dDepartment of Microbiology

^ePharmacology Graduate Program Medical School, University of Minnesota, Minneapolis, Minnesota 55455

Abstract

Ribonucleotide reductase inhibitors enhance the anti-HIV-1 activities of a variety of nucleoside analogs, including those that act as chain terminators and those that increase the HIV-1 mutation rate. However the use of these ribonucleotide reductase inhibitors is limited by their associated toxicities. The hydroxylated phytostilbene resveratrol has activity in a host of systems including inhibition of ribonucleotide reductase and has minimal toxicity. Here we synthesized derivatives of resveratrol and examined them for anti-HIV-1 activity and their ability to enhance the antiviral activity of decitabine, a nucleoside analog that decreases viral replication by increasing the HIV-1 mutation rate. The data demonstrates six of the derivatives have anti-HIV-1 activity greater than resveratrol. However, only resveratrol acted in synergy with decitabine to inhibit HIV-1 infectivity. These results reveal novel resveratrol derivatives with anti-HIV-1 activity that may have mechanisms of action that differ from the drugs currently used to treat HIV-1.

Keywords

HIV-1; Resveratrol; Antiviral; Mutagenesis; Decitabine

Human immunodeficiency virus type 1 (HIV-1), the causative agent of AIDS, currently infects more than 30 million individuals worldwide.¹ While drug therapy effectively suppresses viral replication, resistance to these drugs is a significant problem and necessitates the development of novel drug therapies.² The development of drug resistance is facilitated by the high mutation rate of HIV-1 as well as the large number of virus particles produced by infected cells. Although the mutation rate facilitates emergence of drug resistance, it also renders HIV-1 particularly susceptible to modest increases in

© 2012 Elsevier Ltd. All rights reserved

*To whom correspondences should be addressed: Steven E. Patterson, patte219@umn.edu Christine L. Clouser, cclouser@umn.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

mutation rate.³ An antiviral strategy termed lethal mutagenesis aims to take advantage of this susceptibility by intentionally increasing the mutation rate of RNA viruses such that these viruses are unable to replicate their genome with enough fidelity to remain infectious.⁴ A number of RNA viruses have been shown to be susceptible to lethal mutagenesis including hepatitis C virus, poliovirus, vesicular stomatitis virus and HIV-1.^{5–10} In fact, hepatitis C virus is treated with ribavirin, a drug that has been shown to inhibit viral replication through lethal mutagenesis in cell culture.^{11, 12} Whether ribavirin has the same mechanism in vivo is not yet clear.^{13, 14}

Although none of the clinically approved anti-HIV-1 therapies act through lethal mutagenesis, we have reported the ability of the cytosine analog decitabine (5-aza-2'-deoxycytidine) and its riboside analog, 5-azacytidine to lethally mutagenize HIV-1 in a cell culture system.^{10, 15} Additionally, we have demonstrated that select ribonucleotide reductase inhibitors (RNRI) such as hydroxyurea and gemcitabine dramatically enhance the antiviral activity of decitabine.¹⁵ RNRI have also been shown to increase the antiviral activity of nucleoside analogs that act as chain terminators such as zidovudine and didanosine.^{10, 16, 17} RNRI may increase the anti-HIV-1 activity of nucleoside analogs by decreasing endogenous nucleotide concentrations thereby increasing incorporation of the antiviral nucleoside analog. Although gemcitabine and hydroxyurea are clinically approved, their use is limited by the associated toxicities.^{18–20}

Resveratrol (Figure 1, 1a) is a natural product that is well tolerated and has a number of biological activities including the ability to inhibit HIV-1 replication.^{21–23} Resveratrol's anti-HIV-1 activity has been related to its ability to increase activity of SIRT1, a protein that may decrease transcription of the proviral genome.^{23, 24} Additionally, resveratrol synergistically increased the antiviral activity of nucleoside derivatives and this anti-HIV-1 activity may be attributed to its ability to inhibit RNRI.²⁵ Besides being a RNRI with anti-HIV-1 activity, resveratrol has limited toxicity and is relatively inexpensive, making it a strong lead compound for the development of new anti-HIV-1 compounds that could be used alone or in combination with nucleoside analogs such as decitabine.

Using resveratrol as a lead compound, 15 derivatives were screened against HIV-1 alone and in combination with decitabine using an assay that quantifies their ability to inhibit HIV-1 infectivity within a single round of replication. We report here the anti-HIV-1 activity of six of the resveratrol derivatives and demonstrate that resveratrol potentiates the antiviral activity of decitabine.

Compounds **1a** and **1b** were purchased from Sigma-Aldrich and used without further purification. Compound **2** was purchased from Tokyo Chemical Industry. Compounds **6**², and **8**² were prepared following literature procedures. The synthesis of 5-membered heterocyclic compounds **3**, **4** and **5** are as follows (Scheme 1). Aldehyde **13** was converted to the corresponding imidoyl chloride before cyclization with 1-Ethynyl-3,5-dimethoxybenzene. Deprotection with boron trifluoride afforded the isoxazole **3**. The 1, 4-substituted triazole **4**, was accessed through the corresponding azide precursor by copper catalyzed Huisgen [3+2] cycloaddition with 1-Ethynyl-3,5-dimethoxybenzene, followed by deprotection. The pyrrole analogue **5** was synthesized by condensation of 1,3-dicarbonyl intermediate with methyl amine followed by treatment with boron tribromide.

Derivatives **7**, **9**, **10** and **12** were prepared (Scheme 2) by employing the palladium catalyzed Suzuki-Miyaura cross coupling reaction. Thus, 3,5-dimethoxyphenylboronic acid **16** was reacted with 4-bromiodobenzene followed by a second coupling reaction with 4-pyridylboronic acid to afford polyaromatic **17**. Treatment of the boronic acid **16** with 6-bromoisoquinoline generated intermediate 6-phenylisoquinoline **18**. Benzofuran **19a** and

benzothiophene **19b** were synthesized in a similar manner from 2,3-dibromoheteroaromatics respectively. Mono-coupling with 3,5-dimethoxyphenylboronic acid was highly selective for the 2-position, followed by coupling with second boronic acid to give oxygen and sulfur derivatives, respectively. 2,5-aryl substituted pyrimidine **20**, was synthesized from 2,5-bromochloro pyrimidine, first by coupling to the bromide, then chloride with dimethoxy- and methoxy- boronic acids, respectively. Finally, the demethylation of the methoxy derivatives **17–20** was achieved with boron tribromide to afford compounds **7**, **9**, **10a,b** and **12a**. In a similar fashion (Scheme 3), the regioisomers of compounds **10a,b** and **12a** were synthesized by inverting the order of the boronic acid coupling partner followed by deprotection to give compounds **11a,b** and **12b**.

The antiviral activity of resveratrol and its derivatives was examined using the single-round replication assay^{10, 15} where marker genes present in the HIV-1 vector were used to assess infectivity and mutant frequency in the presence or absence of compounds. Six compounds demonstrated concentration-dependent inhibition of HIV-1 infectivity with EC₅₀s below 75 μ M (Table 1). Consistent with a previous report,²³ resveratrol showed anti-HIV-1 activity which was concentration-dependent (Fig 2). However the EC₅₀ of resveratrol was relatively high (>75 μ M). Resveratrol and the six compounds showing improved potency were examined for cytotoxicity as described the supplementary information. The data show that **1b** and **6** had an approximate 5-fold or greater selectivity index relative to the other derivatives.

We next evaluated the ability of resveratrol and three derivatives (**1b**, **11b**, and **6**) to inhibit HIV-1 replication when used in combination with decitabine, a mutagenic nucleoside with anti-HIV-1 activity. Decitabine and each derivative was used at a concentration that would have minimal anti-HIV-1 activity when used individually (Table 2) and examined for the ability of the combination to 1) enhance the antiviral activity of decitabine, and 2) increase the mutant frequency of HIV-1 using the single cycle assay we described previously.^{10, 15}

Mutant frequencies of these compounds were calculated as described in the supplementary material. The data, (Table 2), indicate that resveratrol was the only compound that potentiated the antiviral activity of decitabine while increasing HIV-1 mutant frequency. While the average mutant frequency increased when either resveratrol or **11b** was used in combination with decitabine compared to the no drug control, this was not statistically different than the mutant frequency seen with decitabine alone.

To further examine the ability of resveratrol to act in synergy with decitabine to inhibit HIV-1 activity, we used the MacSynergy II program.²⁶ MacSynergy II determines if the interaction between two compounds can be described as additive, antagonistic, or synergistic. A 10 by 7 matrix was used to assess the anti-HIV-1 activity of decitabine (0–800 nM) and resveratrol (0–100 μ M) alone and in combination. The MacSynergy II program calculates theoretical additive interactions from the individual dose responses. This calculated additivity which represents predicted anti-HIV-1 activity of the drug combinations was subtracted from the experimental data to reveal regions of synergy. Interactions that were additive are expected to lie on a zero plane of additivity (since predicted additive subtracted from experimental data would equal zero in cases of additivity), while any peaks above the plane of additivity indicate areas of synergy. Similarly, and peaks below the plane of additivity represent areas of antagonism. The data was assessed statistically by using the 95% confidence intervals around the experimental dose-responses. Synergy was considered to be significant if the lower 95% confidence limit of the experimental data was still greater than the calculated additive surface. Figure 3 shows that all combinations of resveratrol and decitabine lie above the plane of additivity

with the highest peaks found at combinations containing between 10 and 60 μ M of resveratrol and between 50 and 200 nM of decitabine.

These results indicate that the combination of resveratrol and decitabine are highly synergistic. The ability of resveratrol and decitabine to synergistically decrease HIV-1 infectivity could correlate with their ability to potentiate cellular toxicity. Therefore, the MacSynergy II program was used to assess the possibility that decitabine and resveratrol act synergistically to induce cell toxicity. As shown in Figure 3, the combinations of resveratrol and decitabine that showed the highest antiviral synergy, did not act synergistically to induce cellular toxicity.

In summary, we have synthesized novel resveratrol derivatives and discovered six with anti-HIV-1 activity superior to that of resveratrol. More importantly we have demonstrated that the combination of resveratrol and decitabine act synergistically to inhibit HIV-1 infectivity without a corresponding synergistic increase in cellular toxicity. Future studies will address why resveratrol, but not its derivatives potentiate the antiviral activity of decitabine

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported by a University of Minnesota Academic Health Center Translational Research Grant as well as by NIH Grant GM56615. C.L.C. was supported in part from NIH Grant T32 CA09138 (Cancer Biology Training Grant); M.A.B. was supported in part from NIH Grant T32 GM008700 (Chemistry-Biology Interface Training Grant).

References and notes

1. (UNAIDS), J. U. N. P. o. H. A. WHO. 2010; Vol. 2010
2. Hammer SM, Eron JJJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA. JAMA. 2008; 300:555. [PubMed: 18677028]
3. Coffin JM. Science. 1995; 267:483. [PubMed: 7824947]
4. Drake JW, Holland JJ. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96:13910. [PubMed: 10570172]
5. Crotty S, Andino R. Microbes and Infection. 2002; 4:1301. [PubMed: 12443894]
6. Graci JD, Harki DA, Korneeva VS, Edathil JP, Too K, Franco D, Smidansky ED, Paul AV, Peterson BR, Brown DM, Loakes D, Cameron CE. Journal of Virology. 2007; 81:11256. [PubMed: 17686844]
7. Loeb LA, Essigmann JM, Kazazi F, Zhang J, Rose KD, Mullins JI. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96:1492. [PubMed: 9990051]
8. Ruiz-Jarabo CM, Ly C, Domingo E, de la Torre JC. Virology. 2003; 308:37. [PubMed: 12706088]
9. Smith RA, Loeb LA, Preston BD. Virus Research. 2005; 107:215. [PubMed: 15649567]
10. Dapp MJ, Clouser CL, Patterson S, Mansky LM. Journal of Virology. 2009; 83:11950. [PubMed: 19726509]
11. Severson WE, Schmaljohn CS, Javadian A, Jonsson CB. Journal of Virology. 2003; 77:481. [PubMed: 12477853]
12. Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, Chung RT. Journal of Virology. 2002; 76:8505. [PubMed: 12163570]
13. Cuevas JM, Gonzalez-Candelas F, Moya A, Sanjuan R. Journal of Virology. 2009; 83:5760. [PubMed: 19321623]

14. Lutchman G, Danehower S, Song BC, Liang TJ, Hoofnagle JH, Thomson M, Ghany MG. *Gastroenterology*. 2007; 132:1757. [PubMed: 17484873]
15. Clouser CL, Patterson SE, Mansky LM. *Journal of Virology*. 2010; 84:9301. [PubMed: 20610712]
16. Sumpter LR, Inayat MS, Yost EE, Duvall W, Hagan E, Mayhew CN, Elford HL, Gallicchio VS. *Antiviral Research*. 2004; 62:111. [PubMed: 15130534]
17. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, Gallo RC. *Science*. 1994; 266:801. [PubMed: 7973634]
18. Davidoff S, Shah RD, Arunabh T. *Respiratory Medicine*. 2006; 100:760. [PubMed: 16199150]
19. Gupta N, Ahmed I, Steinberg H, Patel D, Nissel-Horowitz S, Mehrotra B. *American Journal of Clinical Oncology*. 2002; 25:96. [PubMed: 11823707]
20. Lisziewicz J, Foli A, Wainberg M, Lori F. *Drug Safety*. 2003; 26:605. [PubMed: 12814330]
21. Heredia A, Davis C, Redfield R. *Journal of Acquired Immune Deficiency Syndromes*. 2000; 25:246. [PubMed: 11115955]
22. Wang LX, Heredia A, Song H, Zhang Z, Yu B, Davis C, Redfield R. *Journal of Pharmaceutical Sciences*. 2004; 93:2448. [PubMed: 15349955]
23. Zhang HS, Zhou Y, Wu MR, Zhou HS, Xu F. *Life Sciences*. 2009; 85:484. [PubMed: 19664641]
24. Zhang HS, Wu MR. *Virus Research*. 2009; 146:51. [PubMed: 19720090]
25. Fontecave M, Lepoivre M, Elleingand E, Gerez C, Guittet O. *FEBS Letters*. 1998; 421:277. [PubMed: 9468322]
26. Prichard MN, Shipman C Jr. *Antiviral Research*. 1990; 14:181. [PubMed: 2088205]

Figure 1.
Resveratrol and analogues

Figure 2. Resveratrol inhibits HIV-1 in a concentration-dependent manner. The data shows the average $\pm$ standard deviation of 3 independent experiments.

Figure 3.
Resveratrol and decitabine act synergistically to inhibit HIV-1 infectivity in the absence of cellular toxicity.

Scheme 1.

Reagents and conditions: (i) (a) $\text{NH}_2\text{OH}\cdot\text{HCl}$, NaHCO_3 ; (b) NCS ; (ii) (a) 1-Ethynyl-3,5-dimethoxybenzene, NEt_3 ; (b) 1M BBr_3 , DCM, rt, 20 h; (iii) NaN_3 , cat. CuSO_4 ; (iv) (a) 1-Ethynyl-3,5-dimethoxybenzene, sodium ascorbate; (b) 1 M BBr_3 , DCM, rt, 20 h; (v) 3,5-dimethoxy benzaldehyde, NEt_3 , triazolium salt; (vi) (a) $\text{NH}_2\text{Me}\cdot\text{HCl}$, AcOH, p-TsOH; (b) 1 M BBr_3 , DCM, rt, 20 h.

Scheme 2.

Reagents and conditions: (i) Pd(PPh₃)₄, 2 M Na₂CO₃, toluene/EtOH 3:1, reflux, 6 h; (ii) 1 M BBr₃, DCM, rt, 20 h.

Scheme 3.

Reagents and conditions: (i) Pd(PPh₃)₄, 2 M Na₂CO₃, toluene/EtOH 3:1, reflux, 6 h; (ii) 1 M BBr₃, DCM, rt, 20 h.

Table 1Anti-HIV-1 activity (EC₅₀) and toxicity (TC₅₀) of resveratrol and derivatives.

Compound	EC ₅₀ (μM) ^a	TC ₅₀ (μM) ^b	SI ^c
1a	>75	>300	ND
1b	21.4 (17.8–25.1)	>400	>18.7
2	>75	ND	ND
3	>75	ND ^d	ND
4	>75	ND	ND
5	>75	ND	ND
6	8.8 (7.2–10.9)	179 (107–298)	20.3
7	>100	ND	ND
8	>75	ND	ND
9	>75	ND	ND
10a	35.0 (25.9–47.3)	84.8 (75.1–95.7)	2.4
10b	34.4 (28.3–41.9)	131 (109–158)	3.8
11a	65.1 (56.4–75.2)	108 (95.2–123)	1.5
11b	45.1 (31.1–65.5)	118 (93.7–148)	2.6
12a	>75	ND	ND
12b	>75	ND	ND

^aThe concentration of compound that inhibits 50% of HIV-1 infection. The 95% Confidence Intervals are shown in parentheses after the EC₅₀ value.

^bConcentration of compound that induces toxicity in 50% of the host cells.

^cSelectivity index: TC₅₀/EC₅₀

^dNot determined.

Table 2

Effect of Compounds on Infectivity and HIV-1 Mutant Frequency

Compound (concentration)	% Infected Cells ^a	Mutant Frequency ^b
ND	100	1.00
Dec (70 nM)	93±18	1.26 ±0.23
1a (20 µM)	91±15	1.08±0.22
1a (20 µM) + Dec (70 nM)	36±18 ^c	1.96±0.78
1b (6 µM)	88±12	1.16±0.22
1b (6 µM) + Dec (70 nM)	71±15	1.54±0.53
6 (6 µM)	96±14	1.10±0.09
6 (6 µM) + Dec (70 nM)	74±16	1.72±0.72
11b (30 µM)	99±14	1.08±0.12
11b (30 µM) + Dec (70 nM)	80±34	1.94±0.69

^a ND (No Drug) was set to 100% and all others converted as described in the supplementary information. The data show the mean ± Standard Deviation.

^b ND (No Drug) was set to 1.00 and all others converted as described in supplementary information. The data show the mean ± Standard Deviation.

^c Statistically significant difference from individual drug treatment by One-Way ANOVA followed by Tukey's post-test with a p<0.05 considered significant.